Inventiva S.A.
lanifibranor
metabolic dysfunction-associated steatohepatitis (MASH)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on lanifibranor for metabolic dysfunction-associated steatohepatitis (MASH) is expected Date TBD.
Primary source
· SEC 6-K
verified 12h ago
“Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH.”